Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

alpha-Synuclein affects the MAPK pathway and accelerates cell death.

A Iwata1, M Maruyama, I Kanazawa

  • 1Laboratory for CAG Repeat Diseases, Molecular Neuropathology Group, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-shi, Saitama 351-0198, Japan.

The Journal of Biological Chemistry
|September 19, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?

The journal of prevention of Alzheimer's disease·2024
Same author

Usability of a Web-Based Registry for Preclinical Alzheimer's Disease: Implications from a Cross-Sectional Online Survey.

The journal of prevention of Alzheimer's disease·2024
Same author

Characterization of a retroreflector array for 320-GHz interferometer system in Heliotron J.

The Review of scientific instruments·2023
Same author

Development and initial results of 320 GHz interferometer system in Heliotron J.

The Review of scientific instruments·2022
Same author

Measurement of Pa<sub>α</sub> line from pellet ablation cloud in Heliotron J.

The Review of scientific instruments·2022
Same author

Three-dimensional dynamics of fluctuations appearing during pellet ablation process around a pellet in a fusion plasma experiment.

Scientific reports·2022

Alpha-synuclein accumulation in synucleinopathies impairs mitogen-activated protein kinase (MAPK) signaling. This disruption leads to cell death, suggesting a novel therapeutic target for these neurodegenerative diseases.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Cell Biology

Background:

  • Insoluble alpha-synuclein aggregates are hallmarks of Parkinson's disease and related synucleinopathies.
  • The precise mechanisms linking alpha-synuclein accumulation to disease pathogenesis remain incompletely understood.
  • Mitogen-activated protein kinases (MAPKs) are crucial signaling molecules involved in cellular responses, including survival and stress.
  • Previous work indicated alpha-synuclein overexpression impacts Elk-1 phosphorylation, a process mediated by MAPKs.

Purpose of the Study:

  • To investigate the relationship between alpha-synuclein expression and MAPK signaling pathways.
  • To elucidate the role of MAPK signaling in alpha-synuclein-induced cellular dysfunction and death.
  • To explore potential therapeutic strategies targeting the MAPK pathway in synucleinopathies.

Related Experiment Videos

Main Methods:

  • Utilized ecdysone-inducible neuro2a cell lines for controlled alpha-synuclein expression.
  • Assessed MAPK phosphorylation levels in cells with and without alpha-synuclein overexpression.
  • Examined cell viability under varying serum concentrations and in the presence of MAPK inhibitors (U0126) or activators (constitutively active MEK-1).

Main Results:

  • Cells overexpressing alpha-synuclein exhibited reduced levels of phosphorylated MAPKs.
  • Alpha-synuclein-expressing cells showed increased susceptibility to cell death under serum-deprived conditions.
  • Inhibition of MAPK signaling exacerbated cell death in alpha-synuclein-expressing cells, while activation of the pathway rescued viability.
  • Alpha-synuclein appears to reduce the availability of active MAPK signaling molecules.

Conclusions:

  • Alpha-synuclein negatively regulates the MAPK signaling pathway by decreasing active MAPK levels.
  • Dysregulation of MAPK signaling downstream of alpha-synuclein accumulation contributes to cellular pathogenesis in synucleinopathies.
  • Targeting and restoring MAPK pathway activity may represent a viable therapeutic approach for synucleinopathies.